
Radiology Partners and Mosaic Clinical Technologies petition the FDA for clearer regulatory guidelines on imaging AI vision-language models.
Key Details
- 1Radiology Partners and Mosaic Clinical Technologies have submitted a citizen petition to the FDA.
- 2They seek clarity on FDA regulatory status for commercially available vision-language models in diagnostic imaging.
- 3Concerns are raised about the lack of standards for validating performance, safety, and transparency of such AI models.
- 4Current regulatory ambiguity places responsibility and risk on radiologists and downstream users.
- 5The petition asks the FDA to specify whether fine-tuned models require premarket clearance and clarify compliance duties for all stakeholders.
Why It Matters

Source
Radiology Business
Related News

FDA Approves AI Software for Brain Aneurysm Detection on CTA
FDA cleared Uptunity, an AI software, to aid radiologists in detecting brain aneurysms on CT angiography.

SIIM-CAIMI Showcases Advances and Future Trends in Radiology AI
SIIM-CAIMI 2024 explored the future of radiology AI, emphasizing multidisciplinary collaboration and novel research.

DeepHealth AI Suite Expands Radiology Insights Across Modalities
DeepHealth's Radiology AI Suite enables radiologists to detect more findings and extract additional risk and disease progression information from a wide range of imaging exams.